IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: The fact that interleukin-2 in denileukin diftitox (Ontak®) is an agonist ligand of the interleukin-2 receptor in the treatment of cutaneous T-cell lymphoma may support the potential therapeutic use of FL-DM1 [46].